CG Oncology, Inc. (NASDAQ:CGON) Receives $67.83 Average PT from Brokerages

Shares of CG Oncology, Inc. (NASDAQ:CGON) have been given an average recommendation of “Moderate Buy” by the fourteen research firms that are presently covering the stock, Marketbeat reports. One analyst has rated the stock with a sell rating, two have assigned a hold rating and eleven have assigned a buy rating to the company. The average 12-month target price among analysts that have issued a report on the stock in the last year is $67.8333.

Several analysts have commented on the company. Wedbush began coverage on CG Oncology in a report on Thursday, December 11th. They issued an “outperform” rating and a $70.00 price target for the company. Weiss Ratings restated a “sell (d-)” rating on shares of CG Oncology in a report on Wednesday, January 21st. Piper Sandler upped their price target on shares of CG Oncology from $55.00 to $70.00 and gave the stock an “overweight” rating in a research report on Friday, January 16th. Royal Bank Of Canada lifted their price target on shares of CG Oncology from $61.00 to $73.00 and gave the company an “outperform” rating in a report on Wednesday, January 21st. Finally, The Goldman Sachs Group reissued a “buy” rating and set a $82.00 price objective on shares of CG Oncology in a research note on Monday, January 12th.

Insider Activity

In other news, Director Leonard E. Post sold 1,000 shares of the firm’s stock in a transaction dated Monday, November 17th. The stock was sold at an average price of $41.43, for a total value of $41,430.00. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, Director James Mulay sold 11,145 shares of CG Oncology stock in a transaction dated Friday, January 9th. The shares were sold at an average price of $52.47, for a total value of $584,778.15. The disclosure for this sale is available in the SEC filing. Corporate insiders own 7.40% of the company’s stock.

Institutional Investors Weigh In On CG Oncology

Several large investors have recently made changes to their positions in CGON. AQR Capital Management LLC acquired a new stake in CG Oncology in the first quarter valued at approximately $475,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its stake in CG Oncology by 18.1% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 35,522 shares of the company’s stock worth $876,000 after buying an additional 5,442 shares during the period. Millennium Management LLC lifted its holdings in CG Oncology by 139.4% in the 1st quarter. Millennium Management LLC now owns 596,056 shares of the company’s stock worth $14,597,000 after buying an additional 347,055 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its position in CG Oncology by 42.5% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 179,363 shares of the company’s stock valued at $4,393,000 after buying an additional 53,461 shares during the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. grew its stake in shares of CG Oncology by 15.6% during the second quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,945 shares of the company’s stock valued at $77,000 after acquiring an additional 398 shares in the last quarter. Institutional investors and hedge funds own 26.56% of the company’s stock.

CG Oncology Stock Performance

CGON stock opened at $49.20 on Tuesday. The company has a 50 day moving average price of $46.15 and a two-hundred day moving average price of $38.89. The stock has a market capitalization of $3.97 billion, a P/E ratio of -24.12 and a beta of 1.32. CG Oncology has a one year low of $14.80 and a one year high of $57.88.

CG Oncology (NASDAQ:CGON) last posted its quarterly earnings data on Friday, November 14th. The company reported ($0.57) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.57). The business had revenue of $0.16 million for the quarter, compared to analyst estimates of $0.07 million. Research analysts forecast that CG Oncology will post -1.31 earnings per share for the current fiscal year.

CG Oncology Company Profile

CG Oncology, Inc (NASDAQ: CGON) is a clinical-stage biopharmaceutical company focused on the discovery and development of novel antibody-based immunotherapies for the treatment of solid tumor cancers. The company leverages a platform-driven approach to identify and optimize antibody candidates that engage key immune checkpoints and co-stimulatory pathways within the tumor microenvironment. Its pipeline encompasses multiple preclinical programs alongside early-phase clinical trials designed to assess safety, dosing and preliminary anti-tumor activity.

Headquartered in South San Francisco, California, CG Oncology conducts clinical research primarily in the United States, collaborating with leading academic medical centers and contract research organizations to advance its lead candidates.